Interferon alpha-2b biosimilar (PharmBiotek)

干扰素α-2b生物类似药 (PharmBiotek)

Report date: 2022/02/21 14:09:36

Base Information

Drug NameInterferon alpha-2b biosimilar (PharmBiotek)
Drug Alias Name干扰素α-2b生物仿制药 (PharmBiotek)LaferonLaferonum
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMultiple SclerosisUrinary Bladder NeoplasmsBone Marrow Neoplasms +[16] 
Global Approved IndicationsMultiple SclerosisUrinary Bladder NeoplasmsBone Marrow Neoplasms +[16] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUkraine
Original Approved Date2004/01/01
Country/TerritoryUkraine
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPharmbiotek
China Registration ClassN/A

Develop Information

Active CompaniesPharmbiotek
Inactive CompaniesN/A
Active IndicationsMultiple SclerosisUrinary Bladder NeoplasmsBone Marrow Neoplasms +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A